文献速递肝病消化道肿瘤与早癌

检查点抑制剂肝毒性:发病机制与管理

Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
PubMed 文献 · Hepatology · 2023-01-13

免疫检查点抑制剂(ICI)相关肝毒性通常表现为肝细胞酶升高,可发生于2%-25%的ICI治疗患者中;其临床表现和病理与特发性自身免疫性肝炎不同。大剂量糖皮质激素是主要管理手段,但高达30%的高级别肝毒性患者单用糖皮质激素无应答;本文综述发病机制并基于现有文献提出不断演进的管理策略。

要点

  • ICI相关肝毒性可发生于2%-25%的ICI治疗患者,通常表现为肝细胞酶升高。
  • 大剂量糖皮质激素是主要管理手段,但高达30%的高级别肝毒性患者单用糖皮质激素无应答。
  • 非典型胆汁淤积表现日益被认识,罕见暴发性肝炎病例已有报告,最佳管理仍不确定。

核心结论

  • ICI相关肝毒性通常表现为肝细胞酶升高,可发生于2%-25%的ICI治疗患者中。
  • 大剂量糖皮质激素是主要管理手段,但高达30%的高级别肝毒性患者单用糖皮质激素无应答。
  • 基于现有文献,作者提出不断演进的管理策略,纳入限制过度糖皮质激素暴露的策略,并处理罕见但重要的胆汁淤积性肝炎和暴发性肝衰竭表现。

研究设计与样本

  • 本文为综述,基于现有文献回顾ICI相关毒性(重点为肝毒性)的发病机制理解,并提出管理策略。

主要发现

  • ICI相关肝毒性通常表现为肝细胞酶升高,可发生于2%-25%的ICI治疗患者中。
  • 尽管ICI相关肝毒性在临床和病理上与特发性自身免疫性肝炎不同,对其发病机制的理解仍在不断演进。
  • 大剂量糖皮质激素治疗对许多患者有效,但高达30%的高级别肝毒性患者单用糖皮质激素无应答。
  • 非典型胆汁淤积表现日益被认识,ICI肝毒性所致暴发性肝炎的罕见病例已有报告。

临床怎么用

  • 大剂量糖皮质激素仍是ICI相关肝毒性的主要管理手段。
  • 基于现有文献,作者提出不断演进的管理策略,纳入限制过度糖皮质激素暴露的策略,并处理罕见但重要的胆汁淤积性肝炎和暴发性肝衰竭表现。
  • 作者综述了肝毒性及其治疗对癌症结局的影响,以及对于治疗选择可能有限的患者重新挑战ICI的整体安全性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy, including immune checkpoint inhibitor (ICI) therapy, has been a paradigm shift in cancer therapeutics, producing durable cancer responses across a range of primary malignancies. ICI drugs increase immune activity against tumor cells, but may also reduce immune tolerance to self-antigens, resulting in immune-mediated tissue damage. ICI-associated hepatotoxicity usually manifests as hepatocellular enzyme elevation and may occur in 2%-25% of ICI-treated patients. Although ICI-associated hepatotoxicity is clinically and pathologically distinct from idiopathic autoimmune hepatitis, our understanding of its pathogenesis continues to evolve. Pending greater understanding of the pathophysiology, mainstay of management remains through treatment with high-dose corticosteroids. This approach works for many patients, but up to 30% of patients with high-grade hepatotoxicity may not respond to corticosteroids alone. Furthermore, atypical cholestatic presentations are increasingly recognized, and rare cases of fulminant hepatitis due to ICI hepatotoxicity have been reported. Optimal management for these challenging patients remains uncertain. Herein, we review the current understanding of pathogenesis of ICI-associated toxicities, with a focus on hepatotoxicity. Based on the existing literature, we propose evolving management approaches to incorporate strategies to limit excess corticosteroid exposure, and address rare but important presentations of cholestatic hepatitis and fulminant liver failure. Finally, as ICI hepatotoxicity frequently occurs in the context of treatment for advanced malignancy, we review the impact of hepatotoxicity and its treatment on cancer outcomes, and the overall safety of re-challenge with ICI, for patients who may have limited treatment options.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Cunningham M, Gupta R, Butler M, et al. Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology. 2023. PMID: 36633259. doi:10.1097/HEP.0000000000000045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。